Journal of obesity & metabolic syndromeOct 7, 2026

The Role of Weight-Loss Surgery in the Age of Glucagon-Like Peptide-1 Treatments: Is Surgery Still Needed?

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 8, 2026

Abstract

Nearly one billion adults are affected by obesity, which significantly increases the risk of various diseases.

Metabolic and bariatric surgery (MBS) is an effective treatment for severe obesity, leading to sustained weight loss and remission of related health issues.
Only fewer than 1% of eligible patients currently receive MBS, indicating a substantial gap in treatment access.
Barriers to MBS include limited awareness, misconceptions about surgical risks, and disparities in healthcare access.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have changed medical obesity management, providing effective weight loss but raising concerns about their role alongside MBS.
MBS offers greater and longer-lasting weight loss compared to GLP-1 RAs alone, suggesting that these treatments could be used together rather than in competition.
Integrating MBS and GLP-1 RAs into a comprehensive weight management model may enhance treatment outcomes and broaden access to care.

Simplified

Obesity remains a growing global health crisis, affecting nearly one billion adults worldwide and substantially increasing the risk of cardiometabolic disease, malignancy, and premature mortality. Metabolic and bariatric surgery (MBS) has evolved into an effective and durable treatment for severe obesity, providing sustained weight loss and significant remission of obesity-related comorbidities (i.e., type 2 diabetes mellitus and cardiovascular disease). Despite dramatic improvements in safety, efficacy, and long-term outcomes over time, MBS remains markedly underutilized, reaching fewer than 1% of eligible patients. Persistent barriers include limited patient and provider awareness, misconceptions regarding surgical risk, and significant disparities in access to care. Concurrently, the rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed the medical management of obesity, offering effective pharmacologic weight loss but raising questions regarding their impact on MBS utilization, durability, and cost-effectiveness. Emerging evidence demonstrates that while MBS produces greater and more durable weight loss than GLP-1 RAs alone, these therapies need not be competitive. Rather, GLP-1 RAs may serve as 'neoadjuvant' treatment to optimize surgical candidacy or as adjunctive treatment for inadequate weight loss or postoperative weight regain. This review synthesizes contemporary data on MBS procedures, outcomes, disparities in access, and evolving perceptions of obesity treatment in the GLP-1 RA era. We propose a chronic weight management model that integrates pharmacotherapy, surgery, and multidisciplinary care along a continuous treatment spectrum. Positioning MBS and GLP-1 RAs as complementary modalities within individualized care pathways may improve long-term outcomes, expand access, and better address the complex, chronic nature of obesity.

The Role of Weight-Loss Surgery in the Age of Glucagon-Like Peptide-1 Treatments: Is Surgery Still Needed?

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief